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Objective: Oligoanalgesia is common in emergency departments (EDs), and pain management is of concern for
ED physicians. The aim of this study was to reveal the effect of ketoprofen gel in patients presenting with me-
chanical low back pain to the ED.
Method: All the study patients received intravenous dexketoprofen additional to study drugs. After
dexketoprofen, 2 g of 2.5% ketoprofen gel or placebo was administered to the site with pain and tenderness.
Pain relief at 15 and 30minuteswasmeasuredby visual analog scale scores. Rescue drug need and adverse effects
were also recorded.
Results: A total of 140 patients were enrolled into the study. Themean age of the study patients was 35± 12, and
56% (n = 79) of them were male. The mean pain reduction at 30 minutes was 52 ± 18 for ketoprofen gel and
37 ± 17 for placebo, and ketoprofen gel was better than placebo at 30 minutes (mean difference, 16 mm; 95%
confidence interval, 10-21). Ten patients (14%) in the placebo group and 2 patients (3%) in the ketoprofen gel
group needed rescue drug (P = .35).
Conclusion: Ketoprofen gel improves pain in patients presenting with mechanical low back pain to ED at 30 mi-
nutes in addition to intravenous dexketoprofen when compared to placebo.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Low back pain (LBP) is one of the leading presentations of patients
seeking for pain relief in the emergency department (ED). Nonsteroidal
anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, and skele-
tal muscle relaxants, commonly used as a combination agent, are the
drugs used mostly in treatment of these patients [1].
Ketoprofen is a NSAID with analgesic, antipyretic, and anti-
inflammatory effects. Although the oral form of ketoprofen has been
used widely in musculoskeletal pain, NSAIDs have well-known adverse
effects that are particularly related to long-term use. However, topical
form of ketoprofen, which is thought to have no systemic effects, mini-
mizes the risk of systemic adverse effects [2].nay, and Golcuk Y; study writ-





.tr (K. Tunay),The present study aimed to reveal the effect of 2.5% topical
ketoprofen (gel form) when added to intravenous (IV) dexketoprofen
in patients presenting with mechanical LBP to the ED.2. Material and method
2.1. Study design and setting
This prospective randomized, double-blind study was carried out in
academic EDs of 3 tertiary care hospitals between June and December
2015. The local ethics committee approved the study. The clinicaltrial.
gov ID is NCT02491879. The study was designed as an equivalence trial
comparing the ketoprofen gel to placebo in addition to IV dexketoprofen.2.2. Selection of participants
Patients between 18 and 65 years old presenting with mechanical
LBP, which is defined as the pain located at the low back region and
not radiating to sciatic nerve trace, were accepted to be eligible for the
study. Patients were excluded if they had the following criteria: symp-
tomsmore 24hours, visual analog scale (VAS) score of less than 40, pos-
itive Loseque test or pain radiating to sciatic nerve distribution, allergy
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and denied to give inform consent.
Patients were enrolled into the study consequently 24 hours/7 days
a week. A senior resident decided the eligibility of the patients.
2.3. Interventions
All the study patients received 50 mg IV dexketoprofen (Fastjel,
ARVELES). After IV dexketoprofen, 2 g of 2.5% ketoprofen gel or placebo
was administered over the area with pain and tenderness according to
the group which the patients being assigned. Placebo was identical to
dexketoprofen gel in color, stiffness, and smell. Study drugswere imple-
mented within an area of approximately 5 cm in diameter.
Patients were randomized according to the computerized blocks of
8. The study drugs were preserved in 50-mL syringe labeled as A or B.
The only person aware of the representatives of A and B also prepared
drugs andwas not a part of patient enrollment and drug administration
process. If a patient was eligible for the study, the study nursed took a
number from an opaque bag displaying one of the letters A or B. In ad-
dition, the study drug was administered to the patient by the study
nurse considering these numbers. Physicians, nurses, and patients
were all blinded to the study drugs.
2.4. Methods of measurement
A 100-mm VAS (0, no pain, and 100 mm, the worst pain) with ver-
tical lines intersectingmultiples of 10was used tomeasure the intensityFig. 1. Patient flof pain. Pain measurements of the patients were carried out at baseline,
15 and 30 minutes after the administration of the study drug. Patients
were blinded to the previous VAS scores. Rescue drug needed and side
effects also recorded to the study form.
2.5. Outcome measures
The primary outcome measure was the pain relief at 30 minutes
after the administration of the drug. Secondary outcome measures
were the need for rescue drug, adverse effects secondary to study
drugs, and also pain relief at 15 minutes.
2.6. Statistical analysis
The study data were analyzed in SPSS software. Numeric variables
were presented asmean±SD; and frequent variables, as rates. Normal-
ity analysis was performed by Kolmogorov-Smirnov test, and improve-
ments in pain score were depicted by mean and 95% confidence
intervals (CIs). All variables depicting pain differences other than reduc-
tion of VAS at 15 minutes in placebo group was distributed normally.
Two-group comparison for numeric variables was performed by the
Student t test and χ2 test with continuity correction for categorical var-
iables. For a 17-mm SD and an equivalence limit of 10 mm with 90%
power, at least 63 patients are needed apiece. All the analyses were per-
formed according to the intention-to-treat principle. All the hypotheses
were constructed as 2 tailed, and an α critical value of .05 was accepted
as significant.ow chart.
Table 1
Visual analog scale scores at various time points and change in pain intensity at 15 and 30
minutes for each study arm
Variable Ketoprofen group Placebo group
VAS, mean ± SD
Baseline 74 ± 13 77 ± 14
15 min 47 ± 16 49 ± 20
30 min 21 ± 14 40 ± 20
Change from baseline (VAS), mean (95% CI)
15 min 27 (24-30) 28 (25-31)
30 min 52 (48-57) 37 (33-41)
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A total 285patientswere eligible for the study, and145patientswere ex-
cluded fromthe study forvarious reasons (Fig. 1).Onehundred fortypatients
composed the population, but 1 patient in placebo group quit the EDafter 15
minutes leading to the lack of 30th minute data. The mean age of the study
patients was 35± 12, and 56% (n= 79) of themwere male.
Themeanpain reduction in ketoprofen (27±13mm)andplacebo (28±
13) groups at 15minutes was similar (Table 1). However, the mean pain re-
duction at 30minuteswas 52±18 and 37±17, respectively. (See Figure 2).
Although there was no difference considering the pain reduction at
15 minutes between 2 groups (mean difference, 0.5 mm; 95% CI, −4
to 5), ketoprofen gel was better than placebo at 30 minutes (mean dif-
ference, 16 mm; 95% CI, 10-21). (See Table 2).
Ten patients (14%) in the placebo group and 2 patients (3%) in the
ketoprofen gel group needed rescue drug (P= .35). One patient in the pla-
cebo group statednausea; and1 patient in the ketoprofen gel group, vertigo.
4. Discussion
This study shows that the use of 2.5% topical ketoprofen gel addi-
tional to IV dexketoprofen is associatedwith a significant pain reduction
at 30 minutes in patients presenting with LBP to the ED.Fig. 2. Parallel line plot of study armTopical application of NSAID gels is not a common choice for provid-
ing analgesia in EDs. Intravenous and intramuscular NSAIDs and opioids
are the main agents being used for pain management. However, topical
agents might be an option for ceasing pain because of their safer profile
and topical analgesic effect on the peripheral nervous system. Studies
have shown that topical NSAIDs penetrate the skin and distribute to
the target tissues beneath the application site. The systemic absorption
of topical agents is minimal resulting in less adverse events [3,4].
Patients with LBP commonly present to the ED. Although the IV and
oral NSAIDs are effective choices for LBP, they might be associated with
adverse effects such as ulceration and bleeding in gastrointestinal sys-
tem, impairment of renal function, and hepatic failure. Several studies
have reported that topical NSAIDs (ketoprofen gel or patch, ibuprofen
gel or cream, and diclofenac gel or patch) effectively inhibit cyclooxy-
genase 2 at the tissue levelwhile reducing pain and risk of systemic tox-
icity. Despite the aforementioned data, routine use of topical NSAIDs for
ED patients is still controversial [5–7]. A current Cochranemeta-analysis
by Derry et al [7] reported the effects of topical nonsteroidal anti-
inflammatory agents in acute musculoskeletal pain including sprains,
strains, or sports or overuse-type injuries. They included studies with di-
chotomized outcomes, defined as successful treatment, rather than out-
comes in average. Seven trials studied topical ketoprofen with
approximately 700 patients included into themeta-analysis, and the num-
ber of patients needed to treat for a successful treatment was reported as
3.9.When compared all the nonsteroidal anti-inflammatory topical agents
to placebo for adverse effects by including more than 6000 patients, there
was no difference either for local or systemic adverse effects [7].
Achieving a rapid pain relief is crucial in ED. However, the present
study showed that topical ketoprofen is not superior to placebo at 15mi-
nutes despite the 30-sminute efficiency. This finding may be indicating a
slow onset of effectivity that needs to be clarified by further studies. Slow
onset of action may hinder the use of an analgesic as a single agent.
One patient in each group reported adverse effects, nausea, and ver-
tigo. However, these were most likely related to the pain or IV
dexketoprofen rather than the topical ketoprofen.s at baseline and 30 minutes.
Table 2
Comparison of pain improvements between 2 groups at 15 and 30 minutes
Variable Placebo vs ketoprofen P
Differences from baseline to 15 min, mean (95% CI) 0.5 (−4 to 5) .8
Differences from baseline to 30 min, mean (95% CI) 16 (10-21) .000
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There are several limitations to this study. Although the study was
designed as an equivalence trial, the sample size is not so big that may
lead the findings prone to random error. Pain scores after 30 minutes
were not measured in the present study, and progress of the effect of
topical ketoprofen is not known.
6. Conclusion
In conclusion, concomitant administration of topical ketoprofen gel and
IV dexketoprofen is a simple, well-tolerated therapeutic and effective option
with no serious local or systemic side effects for the treatment of LBP in ED.Acknowledgment
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